Skip to main content
Caplight Logo









Azafaros

Azafaros

Private
LeidenHealthcare & Life Scienceshttps://www.azafaros.com/

Last Round

Series B

May 13, 2025

Total Funding Raised

$174.14M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Azafaros is a biopharmaceutical company developing disease-modifying therapeutics for rare lysosomal storage disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologyrare metabolic diseasessmall moleculelysosomal storage disordersorphan drugsblood-brain barrierclinical-stage biotechdrug discoveryGM2 gangliosidosisNiemann-Pick diseasebiopharmaclinical trialsdrug developmentmetabolic disordersCNS therapeutics

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Azafaros Comparables

Compare Azafaros with similar companies based on industry and business-model similarity.

Azafaros comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
IntraBio
84%
Polaryx Therapeutics
78%
Beren Therapeutics
77%

Azafaros Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BMay 13, 2025
Series AFeb 6, 2020
SeedJul 23, 2018

Key People

Founding team and executive leadership

Stefano Portolano

Chief Executive Officer

Executive Team

Silvia Ragno

Chief Operating Officer

Executive Team

Azafaros Investors

Notable investors and investment history

Azafaros investors
InvestorRounds
Pictet GroupSeries B
Asahi Kasei Pharma Venture CapitalSeries B
BioMedPartnersSeries B, Series A
Asahi Kasei Therapeutics Venture CapitalSeries B
ForbionSeries B, Series A
Seroba Life SciencesSeries B
Forbion VenturesSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 24, 2026

    Monthly visitors increased 204% MoM, reaching 3.9K.

  • Jan 8, 2026

    Will present at J.P. Morgan's 44th Annual Healthcare Conference.

Azafaros Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Azafaros Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Azafaros's valuation, stock price, and market status.

Firmographic Details

HeadquartersLeiden
Employee Range33
Year Founded2018
Last FundingMay 13, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?